Advances in the development of bacterial vector technology

Expert Review of Vaccines

Volumn 2, Issue 1, 2003, Pages 31-43

  Kochi, Sims K ^a,b   Killeen, Kevin P ^b   Ryan, Una S ^a  

^a AVANT Immunotherapeutics Inc   (United States)

^b Bacterial Vaccines   (United States)

Author keywords

Attenuated bacteria; Bacterial vector; BCG; Listeria; Salmonella; Shigella; Vaccine; Vibrio

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL VACCINE; BCG VACCINE; CIRCUMSPOROZOITE PROTEIN ANTIGEN; COLONIZATION FACTOR ANTIGEN; HELICOBACTER PYLORI UREASE ANTIGEN; HEPATITIS B VIRUS ANTIGEN; LISTERIA ANTIGEN; LISTERIA VACCINE; NUCLEOPROTEIN ANTIGEN; O ANTIGEN; SALMONELLOSIS VACCINE; SHIGELLA SONNIE ANTIGEN; SHIGELLA VACCINE; TETANUS TOXIN FRAGMENT C ANTIGEN; UNCLASSIFIED DRUG; VIBRIO VACCINE;

ANTIGEN EXPRESSION; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL STRAIN; BIOLOGICAL WARFARE; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DRUG DELIVERY SYSTEM; FEVER; FOOD SAFETY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; LISTERIA MONOCYTOGENES; LISTERIOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALMONELLA; SALMONELLOSIS; SHIGELLA; SHIGELLOSIS; T LYMPHOCYTE; TUBERCULOSIS; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS; BACTERIAL VACCINES; BCG VACCINE; BIOTERRORISM; CHOLERA VACCINES; DNA, RECOMBINANT; DRUG DESIGN; FOOD CONTAMINATION; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; LISTERIA MONOCYTOGENES; MYCOBACTERIUM BOVIS; PLASMIDS; SAFETY; SALMONELLA ENTERICA; SHIGELLA; T-LYMPHOCYTE SUBSETS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIBRIO;

EID: 0038668917     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.1.31     Document Type: Review

References (106)

1. Kraehenbuhl JP, Neutra MR. Defense of mucosal surfaces: pathogenicity, immunity and vaccines. Curr. Top. Microbiol. Immunol. 236, Springer-Verlag New York Inc., NY, USA (1998).
2. Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh ND. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349, 231-235 (1997).
3. Trach DD, Cam PD, Ke NT et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Vietnam. Bull. World Health Organ. 80(1), 2-8 (2002).
4. Lockman S, Tappero JW, Kenyon TA, Rumisha D, Huebner RE, Binkin NJ. Tuberculin reactivity in a pediatric population with high BCG vaccination coverage. Int. J. Tuberc. Lung Dis. 3(1), 23-30 (1999).
5. Germanier R, Furer E. Isolation and characterization of galE mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141(553) (1975).
6. Guleria I, Teitelbaum R, McAdam RA. Auxotrophic vaccines for tuberculosis. Nat. Med. 2, 334-337 (1996).
7. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173, 1408-1414 (1996).
8. Sansonetti PJ, Arondel A, Fontaine H d'Hauteville, Bernardini ML. OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9, 416-422 (1991).
9. Killeen K, DiRita V. Live attenuated bacterial vaccines. In: New Vaccine Technologies. Ellis R (Ed.). Landes Bioscience, Georgetown, TX, USA (2000).
10. Cancellieri V, Fara GM. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine. J. Infect. Dis. 151(3), 482-484 (1985).
11. Viret J-F, Favre D, Wegmüller B et al. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 67(7), 3680-3685 (1999).
12. Tagliabue A, Nencioni L, Caffarena A et al. Cellular immunity against Salmonella typhi after live oral vaccine. Clin. Exp. Immunol. 62(2), 242-247 (1985).
13. Tacket CO, Sztein MB, Wasserman SS et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect Immun. 68(3), 1196-1201 (2000).
14. Hindle Z, Chatfield SN, Phillimore J. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 70(7), 3457-3467 (2002).
15. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes Infect. 3, 271-1279 (2001). Review of the status of Salmonella typhi vector and vaccine studies in humans.
16. Formal SB, Baron LS, Kopecko DJ, Washington O, Powell C, Life CA. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect. Immun. 34(3), 746-750 (1981).
17. Herrington DA, Verg LVD, Formal SB et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8(4), 353-357 (1990).
18. González C, Hone D, Noriega FR et al. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 13, 927-931 (1994).
19. Tacket CO, Galen J, Sztein MB et al. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin. Immunol. 97(2), 146-153 (2000).
20. Nardelli-Haefliger D, Kraehenbuhl JP et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine. Infect. Immunol. 64(12), 5219-5224 (1996).
21. Tacket CO, Kelly SM, Schödel F et al. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65(8), 3381-3385 (1997).
22. Dipetrillo MD, Tibbetts T, Kleanthous H, Killeen K, Hohmann E. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18, 449-459 (2000).
23. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect. Immun. 68(4), 2135-2141 (2000). The first study to show the potential use of serovar Typhimurium as a vector organism in humans.
24. + expression-cloning vector: stable maintenance and high-level expression of cloned genes in a Salmonella vaccine strain. Biotechnol. 6, 693-697 (1988).
25. Tzschaschel BD, Guzman CA, Timmis KN, de Lorenzo V. An Escherichia coli hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin IIeB subunit by Salmonella typhimurium aroA. Nat. Biotechnol. 14, 765-769 (1996).
26. Hess J, Dietrich G, Gentschev I, Miko D, Goebel W, Kaufmann SHE. Protection against murine listeriosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase. Infect. Immun. 65(4), 1286-1292 (1997).
27. Kwak Y-D, Yoo S-K, Kim EJ. Cell surface display of human immunodeficiency virus type 1 gp120 on Escherichia coli by using ice nucleation protein. Clin. Diagn. Lab. Immunol. 6(4), 499-503 (1999).
28. Jung H-C, Lebeault J-M, Pan J-G. Surface display of Zymomonas mobilis levan sucrase by using the ice-nucleation protein of Pseudomonas syringae. Nat. Biotechnol. 16, 576-580 (1998).
29. Lee J-S, Shin K-S, Pan J-G, Kim C-J. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat. Biotechnol. 18, 645-648 (2000).
30. Coulson NM, Fulop M, Titball RW. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 12(15), 1395-1401 (1994).
31. Beyer W, Griffin KE, Garmory HS, Titball RW. Improvements in the development of live Salmonella vectors for the delivery of vaccine candidates against B. anthracis. Board 39B. In: Abstracts of the Fourth International Conference on Anthrax, Saint John's College, Andover, MD, USA (2001).
32. Kim S, Kim H, Chai Y. Cell surface display of Bacillus anthracis Protective Antigen on Escherichia coli by using ice nucleation protein. Board 36A in Abstracts of the Fourth International Conference on Anthrax, Saint John's College, Andover, MD, USA (2001).
33. Williamson ED, Eley SM, Griffin KF. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol. Med Microbiol. 12, 223-230 (1995).
34. Titball RW, Howells AM, Oyston PCF, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun. 65(5), 1926-1930 (1997).
35. Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog. 23(3), 167-79 (1997).
36. Pfeifer JD, Wick MJ, Roberts RL, Findley K, Normark SJ, Harding CV. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361, 359-362 (1993).
37. Wick MJ, Harding CV, Twesten NJ, Normark SJ, Pfeifer JD. The phoP locus influences processing and presentaion of Salmonella typhimurium antigens by acitvated marcrophages. Mol. Microbiol. 16, 465-476 (1995).
38. Gómez-Duarte OG, Pasetti MF, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect. Immun. 69(2), 1192-1198 (2001).
39. Dietrich G, Gentschev I, Hess J, Ulmer JB, Kaufmann SH, Goebel W. Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol. Today 20(6), 251-253 (1999).
40. Darji A, Guzman CA, Gerstel B et al. Oral somatic transgene vaccination using attenuated S. typhimurium Cell 91(6), 765-775 (1997).
41. Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood 92(9), 3172-3176 (1998).
42. Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM. Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20(3-4), 623-629 (2001).
43. Jain KK. Use of bacteria as anticancer agents. Expert Opin. Biol. Therap. 1(2), 291-300 (2001).
44. Saltzman DA, Katsanis E, Heise CP et al. Antitumor mechanisms of attenuated Salmonella typhimurium containing the gene for human interleukin-2: a novel antitumor agent? J. Pediatr. Surg. 32(2), 301-306 (1997).
45. Low KB, Ittensohn M, Le T et al. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat. Biotechnol. 17, 37-41 (1999)
46. Zheng LM, Luo X, Feng M et al. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol. Res. 12, 127-135 (2000).
47. Hassan JO, Curtiss III R. Control of colonization by virulent Salmonella typhimurium by oral immunization of chickens with avirulent Δcya Δcrp S. typhimurium. Res. Microbiol. 141, 839-850 (1990).
48. Hassan JO, Curtiss III R. Development and evaluation of an experimental vaccination program using live avirulent Salmonella typhimurium to protect immunized chickens against challenge with homologous and heterologous Salmonella serotypes. Infect. Immun. 62(12), 5519-5527 (1994).
49. Hassan JO, Curtiss III R. Effect of vaccination of hens with an avirulent Salmonella typhimurium on immunity of progeny challenged with wild-type Salmonella strains. J. Bacteriol. 64, 938-944 (1996).
50. Coster TS, Hoge CW, VanDeVerg LL et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67, 3437-3443 (1999).
51. Kotloff KL, Noriega F, Losonsky GA et al. Safety, immunogneicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun. 64, 4542-4549 (1996).
52. Kotloff KL, Taylor DN, Sztein MB et al. Phase I evaluation of ΔvirG Shigella sonnei live, attenuated oral vaccine strain WRSS1 in healthy adults. Infect. Immun. 70(4), 2016-2021 (2002).
53. Kotloff KL, Noriega FR, Samandari T et al. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun. 68, 1034-1039 (2000).
54. Barzu S, Arondel J, Guillot S, Sansonetti PJ, Phalipon A. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602. Infect. Immun. 66, 77-82 (1998).
55. Noriega FR, Losonsky G, Wang JY, Formal SB, Levine MM. Further characterization of ΔaroA and ΔvirG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect. Immun. 64, 23-27 (1996).
56. Sizemore DR, Branstrom A, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299-302 (1995). Attenuated Shigella was the first bacterial vector used to deliver plasmid DNA.
57. Sizemore DR, Branstrom A, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 15, 804-807 (1997).
58. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J. Immunol. 162, 1603-1610 (1999).
59. Kaufmann SH. Immunity against intracellular bacteria. In: Annual Reviews of Immunology 11, 129-163 (1993).
60. Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JR. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Natl Acad Sci. USA 92, 3987-3991 (1995).
61. Thompson RJ, Bouwer HGA, Portnoy DA, Frankel FR. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires D-alanine for growth. Infect. Immun. 66(8), 3552-3561 (1998).
62. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JR, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70(7), 3592-3601 (2002).
63. + T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int. Immunol. 7, 797-805 (1995).
64. Shen H, Miller JF, Fan X, Kolwyck D, Ahmed T, Harty JT. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell 92, 535-545 (1998).
65. Paterson Y, Ikonomidis G. Recombinant Listeria monocytogenes cancer vaccines. Curr. Opin. Immunol. 8, 664-669 (1996).
66. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor challenge and causes regression of established tumors. Nat. Med. 1, 471-477 (1995).
67. Dietrich G, Bubert A, Gentschev I et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attentuated suicide Listeria monocytogenes. Nat. Biotechnol. 16, 181-185 (1998).
68. Stover CK, de la Cruz VF, Fuerst TR et al. New use of BCG for recombinant vaccines. Nature 351, 456-460 (1991).
69. Lagranderie M, Winter N, Balazuc AM, Gicquel B, Gheorghiu M. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Retroviruses 14, 1625-1633 (1998).
70. Stover CK, Bansal GP, Hanson MS et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med. 178, 197-209 (1993).
71. Edelman R, Palmer K, Russ KG et al. Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 17, 904-914 (1998).
72. Lussow AR, Del GG, Renia L et al. Use of tuberculin purified protein derivative-Asn-Ala-Asn-Pro conjugate in bacillus Calmette-Guerin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants. Proc. Natl. Acad. Sci. USA 87, 2960-2964 (1990).
73. Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merosoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon-γ and parasite-specific antibodies. J. Exp. Med. 188(5), 845-854 (1998).
74. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SHE. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl. Acad. Sci. USA 95, 5299-5304 (1998).
75. Kaufmann SHE. Fundamental Immunology. Paul WE (Ed.). Raven Press, New York, NY, USA (1997).
76. Pearson GD, Woods A, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Proc. Natl. Acad. Sci. USA 90, 3750-3754 (1993).
77. Levine MM, Kaper JB, Herrington D et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2, 467-470 (1988).
78. Taylor DN, Killeen KP, Hack DC et al. Development of a live, oral, attenuated vaccine against E1 Tor cholera. J. Infect. Dis. 170, 1518-1523 (1994).
79. Butterton JR, Beattie DT, Gardel CL et al. Heterologous antigen expression in Vibrio cholerae vector strains. 63, 2689-2696 (1995).
80. Butterton JR, Ryan ET, Acheson DWK, Calderwood SB. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect. Immun. 65, 2127-2135 (1997).
81. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65, 2941-2949 (1997).
82. Acheson DWK, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. Infect. Immun. 64, 355-357 (1996).
83. inaba deletion mutants of Vibrio cholerae expressing the Shigella serotype C O polysaccharice. Infect. Immun. 64(2), 576-584 (1996).
84. Hess J, Gentschev I, Miko D et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc. Natl. Acad. Sci. USA 93, 1458-1463 (1996).
85. Connell TD, Metzger DJ, Wang M, Jobling MC, Holmes RK. Initial studies of the structural signal for extracellular transport of cholera toxin and other proteins recognized by Vibrio cholerae. Infect. Immun. 63, 4091-4098 (1995).
86. Backstrom M, Lebens M, Schodel F, Holmgren J. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene 149, 211-217 (1994).
87. Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier and adjuvant. Am. J. Trop. Med. Hygiene 50(Suppl.) 42-54 (1994).
88. Ryan ET, Butterton JR, Zhang T, Baker MA, Stanley SL, Calderwood SB. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti-V. cholerae antibody responses in mice. Infect. Immun. 65, 3118-3125 (1997).
89. Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect. Immun. 65, 2491-2449 (1997).
90. Ryan ET, Crean TI, Kochi SK et al. Development of a ΔgInA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect. Immun. 68, 221-226 (2000).
91. Attridge SR, Darles R, LaBrooy T. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine 15, 155-162 (1997).
92. Bao JX, Clements JD. Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. Infect. Immun. 59, 3841-3845 (1991).
93. Whittle BL, Verma NK. The immune reponse to a B-cell epitope delivered by Salmonella is enhanced by prior immunological experience. Vaccine 15, 1737-1740 (1997).
94. Kohler JJ, Pathangey LB, Bgillespie SR, Brown TA. Effect of pre-existing immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar Typhimurium expressing a Porphyromonas gingivalis hemagglutinin. Infect. Immun. 68(6), 3116-3120 (2000).
95. Roberts M, Bacon A, Li J, Chatfield S. Prior immunity to homologous and heterologous Salmonella serotypes suppresses local systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with Salmonella strains expressing fragment C. Infect. Immun. 67, 3810-3815 (1999).
96. Forrest BD. Impairment of immunogenicity of Salmonella typhi Ty21a due to pre-existing cross-reacting intestinal antibodies. In: Advances in Mucosal Immunology. Mestecky J, Russell MW (Eds). Plenum Press: New York, NY, USA (1995).
97. Kollaritsch H, Cryz SJ Jr, Lang AB, Herzog C, Que JU, Wiedermann G. Local and systemic immune responses to combined Vibrio cholerae CVD 103-HgR and Salmonella typhi Ty21a live oral vaccines after primary immunization and reimmunization. Vaccine 18(26), 3031-3039 (2000).
98. Kollaritsch H, Furer E, Herzog C, Wiedermann G, Que JU, Cryz SJ Jr. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect. Immun. 64(4), 1454-1457 (1996).
99. Coster TS, Killeen DP, Waldor MK et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 345(8955), 949-952 (1995).
100. Roland K, Curtiss III R, Sizemore D. Construction and evaluation of a Δcya Δcrp Salmonella typhimurium strain expressing avian pathogenic Escherichia coli O78 LPS as a vaccine to prevent airsacculitis in chickens. Avian Dis. 43, 429-441 (1999).
101. Butterton JR, Ryan ET, Shahin RA, Calderwood SB. Development of a germfree mouse model of Vibrio cholerae infection. Infect. Immun. 64(10), 4373-4377 (1996).
102. Zegers ND, Kluter E, van der Strap H et al. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J. Appl. Microbiol. 87, 309-314 (1999).
103. Medaglini D, Pozzi G, King TP, Fischetti VA. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl. Acad. Sci. USA 92, 6868-6872 (1995).
104. Hess J, Dietrich G, Gentschev I, Miko D, Goebel W, SHE Kaufmann. Protection against murine listeriosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase. Infect. Immun. 65(4), 1286-1292 (1997).
105. Byrd CM, Bolken TC, Jones KF et al. Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine 20(17-18), 2197-2205 (2002).
106. Xiang R, Lode HN, Chao TH et al. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. USA 97(10), 5492-5497 (2000).